Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775 - PubMed
3 days ago
- #lenvatinib
- #pembrolizumab
- #endometrial cancer
- Lenvatinib plus pembrolizumab showed significant improvement in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced endometrial cancer (EC) compared to chemotherapy.
- The 5-year follow-up results demonstrated a 16.7% OS rate with lenvatinib+pembrolizumab versus 7.3% with chemotherapy in mismatch repair-proficient EC, and 36.5% versus 9.8% in mismatch repair-deficient EC.
- Five-year PFS rates were 6.3% versus 2.1% in mismatch repair-proficient EC, 26.4% versus 10.8% in mismatch repair-deficient EC, and 9.8% versus 3.2% in all-comers.
- Treatment-related adverse events led to discontinuation in 32.3% of lenvatinib+pembrolizumab patients versus 5.9% in the chemotherapy group.
- Subsequent systemic anticancer therapy was used by 44.8% in the lenvatinib+pembrolizumab group versus 51.2% in the chemotherapy group.
- The study supports lenvatinib+pembrolizumab as a standard of care for advanced EC, with durable benefits and no new safety signals.